<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02682563</url>
  </required_header>
  <id_info>
    <org_study_id>DC 2015 RED 01</org_study_id>
    <secondary_id>2015-003818-24</secondary_id>
    <nct_id>NCT02682563</nct_id>
  </id_info>
  <brief_title>Renoprotective Effects of Dapagliflozin in Type 2 Diabetes</brief_title>
  <acronym>RED</acronym>
  <official_title>A Randomized, Double-blind, Comparator-controlled Trial to Assess the Effect of 12-week Treatment With Dapagliflozin Versus Gliclazide on Renal Physiology and Biomarkers in Metformin-treated Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.H.H. Kramer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Worldwide, diabetic nephropathy or Diabetic Kidney Disease (DKD), is the most common cause of&#xD;
      chronic and end-stage kidney disease. With the increasing rates of obesity and type 2&#xD;
      diabetes (T2DM), many more patients with DKD may be expected in the coming years. Large-sized&#xD;
      prospective randomized clinical trials suggest that intensified glucose and blood pressure&#xD;
      control, may halt the progression of DKD, both in type 1 diabetes and T2DM. However, despite&#xD;
      the wide use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, a&#xD;
      considerable amount of patients develop DKD during the course of diabetes, indicating an&#xD;
      unmet need for renoprotective therapies. Sodium-glucose linked transporters (SGLT-2)&#xD;
      inhibitors are novel glucose-lowering drugs for the treatment of T2DM. These agents seem to&#xD;
      exert pleiotropic actions 'beyond glucose control', including reduction of blood pressure and&#xD;
      body weight. In addition, SGLT-2 inhibitors decrease proximal sodium reabsorption and&#xD;
      decrease glomerular pressure and albuminuria in rodents and type 1 diabetes patients. In&#xD;
      rodents, SGLT-2 inhibitors also improved histopathological abnormalities associated with DKD.&#xD;
      To date, the potential renoprotective effects and mechanisms of these agents have not been&#xD;
      sufficiently detailed in human type 2 diabetes. The current study aims to explore the&#xD;
      clinical effects and mechanistics of SGLT-2 inhibitors on renal physiology and biomarkers in&#xD;
      metformin-treated T2DM patients with normal kidney function.&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      Randomized, double-blind, comparator-controlled, intervention trial&#xD;
&#xD;
      Study Endpoints:&#xD;
&#xD;
      Renal hemodynamics, i.e. measured glomerular filtration rate (GFR, ml/min) and effective&#xD;
      renal plasma flow (ERPF, ml/min); 24-hour urinary solute excretion; markers of renal damage ;&#xD;
      blood pressure; body anthropometrics; systemic hemodynamic variables (including stroke&#xD;
      volume, cardiac output and total peripheral resistance); arterial stiffness will be assessed&#xD;
      by applanation tonometry, (SphygmoCor®); insulin sensitivity and beta-cell function.&#xD;
&#xD;
      Expected results:&#xD;
&#xD;
      Treatment with the SGLT-2 inhibitor dapagliflozin, as compared to the sulfonylurea (SU)&#xD;
      derivative gliclazide, may confer renoprotection by improving renal hemodynamics, and&#xD;
      decreasing blood pressure and body weight in type 2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design A phase 4, monocenter, randomized, double-blind, comparator-controlled,&#xD;
      parallel-group, mechanistic intervention trial to assess the effect of 12-week treatment with&#xD;
      the sodium-glucose linked transporters (SGLT)-2 inhibitor dapagliflozin versus the&#xD;
      sulfonylurea (SU) derivative gliclazide on renal physiology and biomarkers in&#xD;
      metformin-treated patients with type 2 diabetes mellitus (T2DM)&#xD;
&#xD;
      Recruitment Subjects will be recruited by researcher physicians involved in this trial using&#xD;
      methods that are established practice for all human studies in the Diabetes Center, Vrije&#xD;
      Universiteit (VU) University Medical Center (VUMC), via advertisements, use of a Diabetes&#xD;
      Center database, through the Diabetes Center website.&#xD;
&#xD;
      Screening and eligibility After giving extensive oral and written information, a written&#xD;
      informed consent form will be obtained from the subjects before screening. The screening&#xD;
      procedure will consist of obtaining an extensive medical history, complete physical&#xD;
      examination, blood analysis, urine screening, and a 12-lead electrocardiogram (ECG). Postvoid&#xD;
      residual urine volume will be determined by ultrasonic bladder scan. After inclusion,&#xD;
      participants will enroll in a 4-week run-in period to allow for study effects.&#xD;
&#xD;
      Baseline assessments Seven days prior to this visit, subjects will adhere to a 'normal-salt'&#xD;
      (9 - 12 grams or 150 - 200 mmol per day) and protein (1.5 - 2.0 g/kg per day) diets, in order&#xD;
      to minimize variation in renal physiology due to salt and protein intake. Participants will&#xD;
      abstain from alcohol (24 hours), caffeine (12 hours) and nicotine (12 hours) and heavy&#xD;
      exercise prior to and during visits 2. One day prior to the testing day, subjects will&#xD;
      collect 24-hour urine.&#xD;
&#xD;
      Following an overnight fast, participants will be instructed to drink 500 mL of water, but to&#xD;
      delay all morning-time medication (apart from metformin) until conclusion of the examination&#xD;
      day. After taking subjects history, current weight and blood pressure, intravenous catheters&#xD;
      will be placed in both forearms after which blood and urine will be collected. Thereupon the&#xD;
      combined renal and clamp protocol will commence.&#xD;
&#xD;
      Safety and tolerability: Telephone consultation and follow-up Participants will be asked&#xD;
      about the occurrence of adverse events and the intake of study drugs will be checked.&#xD;
      Furthermore, recent history will be taken, physical examination/anthropometric measurements&#xD;
      performed and blood and urine samples collected.&#xD;
&#xD;
      Study Procedures Renal protocol During this protocol a combined inulin/para-aminohippurate&#xD;
      (PAH)-clearance technique will be performed to examine the glomerular filtration rate (GFR,&#xD;
      ml/min) and effective renal plasma flow (ERPF, ml/min) respectively. In order to examine&#xD;
      tubular function, sodium, potassium, chloride, calcium, magnesium, phosphate, urea and&#xD;
      glucose will be measured in urine (mmol). In addition, urine osmolality will be determined.&#xD;
      Moreover, biomarkers of renal damage (urinary albumin excretion (UAE), Neutrophil&#xD;
      gelatinase-associated lipocalin (NGAL) and Kidney Injury Molecule-1 (KIM-1) will be measured&#xD;
      in urine&#xD;
&#xD;
      Clamp protocol A combined hyperinsulinemic-euglycemic and hyperglycemic clamp will be&#xD;
      performed. During the euglycemic clamp insulin will be infused at 40 microunits/square&#xD;
      meter.minute (mU/m2.min) and glucose will be kept at 5 mmol/l by variable glucose 20%&#xD;
      infusion. This technique allows for renal measurements during normoglycemia in all&#xD;
      participants. After 3 hours of insulin infusion and an one hour rest period for exogenous&#xD;
      insulin to be cleared, glucose will be infused in order to reach a plasma concentration of 15&#xD;
      mmol/l. In this matter, renal tests can be performed under stable hyperglycemia. From the&#xD;
      euglycemic clamp, insulin sensitivity will be determined from the amount of glucose infused&#xD;
      (M-value). Blood will be stored during hyperglycemia in order to be able to obtain measures&#xD;
      of beta-cell function, including 1st phase insulin secretion, 2nd phase insulin secretion and&#xD;
      arginine-induced insulin secretion.&#xD;
&#xD;
      (cardio)vascular measures After an acclimatization period of &gt;5 minutes, blood pressure will&#xD;
      be measured three times at the non-dominant arm, with an automatic oscillometric device&#xD;
      (Dinamap®, General Electric (GE) Healthcare). Systemic hemodynamics will be measured by an&#xD;
      automated, beat-to-beat blood pressure and ECG recording monitor (Nexfin®, BMEYE, Amsterdam,&#xD;
      The Netherlands). Body composition will be assessed by bio impedance analysis using&#xD;
      tetrapolar Soft Tissue Analyzer® (STA, Akern, Florence, Italy). Microvascular function will&#xD;
      be measured by nail fold skin capillary density on the middle finger, and skin blood flow&#xD;
      will be measured using a Laser Doppler probe. Applanation tonometry using the SphygmoCor®&#xD;
      system (Atcor Medical, West Ryde, Australia) will be performed to measure variables of&#xD;
      arterial stiffness at the radial artery of the non-dominant arm.&#xD;
&#xD;
      Fecal examinations Each participant will collect a stool sample before the baseline tests and&#xD;
      once before the long-term follow-up tests. At home, one feces sample must be stored at room&#xD;
      temperature and one in the freezer and when arrived at the CRU, the feces will be stored at&#xD;
      -20⁰C and -80⁰C, respectively.&#xD;
&#xD;
      SAFETY (REPORTING) In accordance with the guidelines of ICH-GCP, the European Clinical Trials&#xD;
      Directive (2001/20/EC) and the local regulations, the investigator will inform the subjects&#xD;
      and the reviewing Ethical Review Board (ERB) if anything occurs, on the basis of which it&#xD;
      appears that the disadvantages of participation may be significantly greater than was&#xD;
      foreseen in the research proposal.&#xD;
&#xD;
      Reporting The investigator will be responsible for reporting the SAEs and SUSARs to the&#xD;
      accredited ERB. This will be done within 15 days after first knowledge, using the specified&#xD;
      web portal ('ToetsingOnline'), which automatically leads to informing the respective national&#xD;
      health authorities. For fatal or life threatening SAEs and SUSARs this term will be 7 days&#xD;
      for a preliminary report ('expedited') with another 8 days for completion of the report.&#xD;
&#xD;
      The involved pharmaceutical company (AstraZeneca) will be notified of all SAEs, pregnancy,&#xD;
      clinical relevant overdosing and adverse events of special interest (AESIs), if any.&#xD;
&#xD;
      Monitoring As required by GCP, a monitoring procedure will be performed in order to oversee&#xD;
      the progress of the clinical trial and ensure that it is conducted, recorded and reported in&#xD;
      accordance with the protocol, standard operating procedures (SOPs), GCP and the applicable&#xD;
      regulatory requirements.&#xD;
&#xD;
      Statistical Analysis Plan All tests of differences between treatments will be conducted at a&#xD;
      two-sided significance level of &lt;0.05. In case of missing data, a multiple imputation&#xD;
      technique will be applied and compared with complete case analysis. The efficacy analysis&#xD;
      population will be based on the per protocol (PP) principle - i.e. all subjects who completed&#xD;
      the entire treatment period using the treatment as originally allocated. Safety analysis will&#xD;
      be performed in all patients who received one or more doses of the study medication.&#xD;
&#xD;
      In order to compare the effects between the two study arms the investigators will perform&#xD;
      t-tests and/or multivariable linear regression models. The latter technique allows us to use&#xD;
      continuous outcome variables and both continuous and dichotomous independent variables. The&#xD;
      efficacy endpoint of interest will be added to the model as dependent variable.&#xD;
&#xD;
      Our primary outcomes will be the most important outcomes for testing the hypothesis that&#xD;
      SGLT-2 inhibitor dapagliflozin versus the SU gliclazide causes an improvement in renal&#xD;
      hemodynamics. The large amount of secondary/exploratory endpoints potentially justifies the&#xD;
      use of corrections for multiple tests. However, there is an increasing debate on whether this&#xD;
      should be done, because of the increased risk of type 2 errors which could lead to&#xD;
      prematurely discarding of potential useful observations. As recently pointed out, in a&#xD;
      hypothesis-generating study - such as the current study - correction for multiple outcomes&#xD;
      can be detrimental. A final decision will be made in the detailed Statistical Analysis Plan&#xD;
      (SAP) prior to the conduction of the analysis.&#xD;
&#xD;
      13. ETHICS The trial will be conducted in accordance with the Declaration of Helsinki (64th&#xD;
      World Medical Association (WMA) General Assembly, Fortaleza, Brazil, October 2013) for&#xD;
      biomedical research involving human subjects and in accordance with ICH-GCP. The investigator&#xD;
      will ensure that all aspects of the institutional ERB review are conducted in accordance with&#xD;
      current institutional, local and national regulations.&#xD;
&#xD;
      Study Medication Participants will be randomized for a 12 week treatment with two different&#xD;
      active study agents. Consequently, independent of treatment allocation, beneficial effects&#xD;
      can be expected, as both SGLT-2 inhibitors and SU derivatives improve glycemic control. Both&#xD;
      study medications have been approved for blood-glucose lowering treatment in T2DM patients&#xD;
      and, based on currently available data, are considered to be safe. Furthermore, SGLT-2&#xD;
      inhibitors in general may decrease blood pressure and body weight compared to gliclazide.&#xD;
&#xD;
      The most common side effects for dapagliflozin are hypoglycemia (especially when used in&#xD;
      combination with a SU derivative or insulin) and genital mycotic- and urinary tract&#xD;
      infections. For gliclazide, hypoglycemia and blurred vision in the initiation phase of&#xD;
      treatment (due to changes in blood glucose levels) are the most common side effects. As in&#xD;
      all drug intervention trials, in this study, the investigators will closely monitor patients&#xD;
      for adverse drug and study events during the follow-up visit and by telephone consultation&#xD;
      according to GCP. Participants can contact the research staff 24 hours a day.&#xD;
&#xD;
      Safety issues The study examinations/tests are considered to be safe. No invasive procedures&#xD;
      (besides intravenous peripheral catheters) are involved. During the study tests, two&#xD;
      'diagnostic agents' (i.e. inulin and PAH) need to be administered; both agents are inert and&#xD;
      have no side effects. The total amount of drawn blood will be 500 mL during a total period of&#xD;
      16 weeks. Side effects are not expected because the blood volume taken per visit is&#xD;
      relatively small, especially in comparison with regular blood donation, with 500 mL per&#xD;
      donation (and is allowed 5 times a year for men and 3 times for women).&#xD;
&#xD;
      Publication policy AstraZeneca will be provided will all intended publication(s) and&#xD;
      abstract(s), preceding submission at least 30 days and 7 days, respectively, AstraZeneca can&#xD;
      make suggestions to change the wording of any planned publication or abstract in relation to&#xD;
      the study and/or the results. The sponsor-investigator is under no obligation to implement&#xD;
      such changes, unless local regulatory requirements specify otherwise.&#xD;
&#xD;
      Data will be presented at relevant national and international scientific meetings, and&#xD;
      published in peer reviewed journals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">September 2018</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glomerular Filtration Rate (GFR) in ml/Min</measure>
    <time_frame>12 weeks</time_frame>
    <description>Calculated from urinary and plasma inulin concentrations, GFR in ml/min</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effective Renal Plasma Flow (ERPF) in ml/Min</measure>
    <time_frame>12 weeks</time_frame>
    <description>Calculated from urinary and plasma para-aminohippurate concentrations, ERPF in ml/min</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fractional Excretion of Sodium in % of Filtered Sodium</measure>
    <time_frame>12 weeks</time_frame>
    <description>Calculated fractional excretions with measured GFR (see above) and urinary and plasma concentrations of sodium. Fractional excretion in % of filtered sodium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional Excretion of Potassium in % of Filtered Potassium</measure>
    <time_frame>12 weeks</time_frame>
    <description>Calculated fractional excretions with measured GFR (see above) and urinary and plasma concentrations of potassium. Fractional excretion in % of filtered potassium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional Excretion of Glucose in % of Filtered Glucose</measure>
    <time_frame>12 weeks</time_frame>
    <description>Calculated fractional excretions with measured GFR (see above) and urinary and plasma concentrations of glucose. Fractional excretion in % of filtered glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Albumin-Creatinine Ratio in mg/mmol</measure>
    <time_frame>12 weeks</time_frame>
    <description>Calculated from measured urinary albumin and creatinin concentrations, in mg/mmol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophil Gelatinase-associated Lipocalin (NGAL)</measure>
    <time_frame>12 weeks</time_frame>
    <description>NGAL (ng/mmoll) measured in urine as a marker of renal damage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney Injury Molecule-1 (KIM-1) in ng/mmol</measure>
    <time_frame>12 weeks</time_frame>
    <description>KIM-1 (ng/mmol) measured in urine as a marker of renal damage</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Body Weight</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measured in kilograms</description>
  </other_outcome>
  <other_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Blood pressure will be measured using an automated oscillometric blood pressure device (Dinamap®) in mmHg</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Diabetic Nephropathies</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin 10mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily treatment with oral dapagliflozin (forxiga) 10mg for 12 consecutive weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gliclazide modified release 30mg once daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily treatment with oral gliclazide MR 30mg for 12 consecutive weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10mg QD</intervention_name>
    <description>Dapagliflozin 10mg once daily for 12 weeks</description>
    <arm_group_label>Dapagliflozin 10mg once daily</arm_group_label>
    <other_name>forxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gliclazide 30mg QD</intervention_name>
    <description>Gliclazide30mg once daily for 12 weeks</description>
    <arm_group_label>Gliclazide modified release 30mg once daily</arm_group_label>
    <other_name>Diamicron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Caucasian*&#xD;
&#xD;
          -  Both genders (females must be post-menopausal; no menses &gt;1 year; in case of doubt,&#xD;
             Follicle-Stimulating Hormone (FSH) will be determined with cut-off defined as &gt;31 U/L)&#xD;
&#xD;
          -  Age: 35 - 75 years&#xD;
&#xD;
          -  BMI: &gt;25 kg/m2&#xD;
&#xD;
          -  HbA1c: 6.5 - 9.0% Diabetes Control and Complications Trial (DCCT) or 48 - 86 mmol/mol&#xD;
             International Federation of Clinical Chemistry (IFCC)&#xD;
&#xD;
          -  Treatment with a stable dose of oral antihyperglycemic agents for at least 3 months&#xD;
             prior to inclusion&#xD;
&#xD;
          -  Metformin monotherapy&#xD;
&#xD;
          -  Combination of metformin and low dose SU derivative**&#xD;
&#xD;
          -  Hypertension should be controlled, i.e. ≤140/90 mmHg, and treated with an ACE-I or ARB&#xD;
             (unless prevented by side effect) for at least 3 months.&#xD;
&#xD;
          -  Albuminuria should be treated with a RAAS-interfering agent (ACE-I or ARB) for at&#xD;
             least 3 months.&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
               -  In order to increase homogeneity ** In order to accelerate inclusion, patients&#xD;
                  using combined metformin/SU derivative will be considered. In these patients, a&#xD;
                  12 week wash-out period of the SU derivative will be observed, only when combined&#xD;
                  use has led to a HbA1c &lt;8% at screening. Subsequently, patients will be eligible&#xD;
                  to enter the study, now using metformin monotherapy, provided that HbA1c still&#xD;
                  meets inclusion criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of unstable or rapidly progressing renal disease&#xD;
&#xD;
          -  Macroalbuminuria; defined as albumin-creatinine ratio of 300mg/g.&#xD;
&#xD;
          -  Estimated GFR &lt;60 mL/min/1.73m2 (determined by the Modification of Diet in Renal&#xD;
             Disease (MDRD) study equation)&#xD;
&#xD;
          -  Current/chronic use of the following medication: thiazolidinedione (TZD), SU&#xD;
             derivative, Glucagon like peptide 1 receptor agonist (GLP-1RA), (dipeptidyl peptidase&#xD;
             4 inhibitor) DPP-4I, SGLT-2 inhibitors, glucocorticoids, immune suppressants,&#xD;
             antimicrobial agents, chemotherapeutics, antipsychotics, tricyclic antidepressants&#xD;
             (TCAs) and monoamine oxidase inhibitors (MAOIs). Subjects on diuretics will only be&#xD;
             excluded when these drugs cannot be stopped for the duration of the study.&#xD;
&#xD;
          -  Volume depleted patients. Patients at risk for volume depletion due to co-existing&#xD;
             conditions or concomitant medications, such as loop diuretics should have careful&#xD;
             monitoring of their volume status.&#xD;
&#xD;
          -  Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) will not be allowed,&#xD;
             unless used as incidental medication (1-2 tablets) for non-chronic indications (i.e.&#xD;
             sports injury, head-ache or back ache). However, no such drugs can be taken within a&#xD;
             time-frame of 2 weeks prior to renal-testing&#xD;
&#xD;
          -  History of diabetic ketoacidosis (DKA) requiring medical intervention (eg, emergency&#xD;
             room visit and/or hospitalization) within 1 month prior to the Screening visit.&#xD;
&#xD;
          -  Current urinary tract infection and active nephritis&#xD;
&#xD;
          -  Recent (&lt;6 months) history of cardiovascular disease, including:&#xD;
&#xD;
               -  Acute coronary syndrome&#xD;
&#xD;
               -  Chronic heart failure (New York Heart Association grade II-IV)&#xD;
&#xD;
               -  Stroke or transient ischemic neurologic disorder&#xD;
&#xD;
          -  Complaints compatible with neurogenic bladder and/or incomplete bladder emptying (as&#xD;
             determined by ultrasonic bladder scan)&#xD;
&#xD;
          -  Severe hepatic insufficiency and/or significant abnormal liver function defined as&#xD;
             aspartate aminotransferase (AST) &gt;3x upper limit of normal (ULN) and/or alanine&#xD;
             aminotransferase (ALT) &gt;3x ULN&#xD;
&#xD;
          -  (Unstable) thyroid disease; defined as free thyroxine (fT4) outside of laboratory&#xD;
             reference values or change in treatment within 3 months prior to screening visit&#xD;
&#xD;
          -  History of or actual malignancy (except basal cell carcinoma)&#xD;
&#xD;
          -  History of or actual severe mental disease&#xD;
&#xD;
          -  Substance abuse (alcohol: defined as &gt;4 units/day)&#xD;
&#xD;
          -  Allergy to any of the agents used in the study&#xD;
&#xD;
          -  Individuals who are investigator site personnel, directly affiliated with the study,&#xD;
             or are immediate (spouse, parent, child, or sibling, whether biological or legally&#xD;
             adopted) family of investigator site personnel directly affiliated with the study&#xD;
&#xD;
          -  Inability to understand the study protocol or give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark HH Kramer, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 5, 2016</study_first_submitted>
  <study_first_submitted_qc>February 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2016</study_first_posted>
  <results_first_submitted>May 20, 2020</results_first_submitted>
  <results_first_submitted_qc>July 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 7, 2020</results_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>M.H.H. Kramer</investigator_full_name>
    <investigator_title>Head of the Internal Medicine department</investigator_title>
  </responsible_party>
  <keyword>SGLT-2 inhibition, Renal, Cardiovascular, Type 2 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
    <mesh_term>Gliclazide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT02682563/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dapagliflozin 10mg Once Daily</title>
          <description>Once daily treatment with oral dapagliflozin (forxiga) 10mg for 12 consecutive weeks.&#xD;
Dapagliflozin 10mg QD: Dapagliflozin 10mg once daily for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Gliclazide Modified Release 30mg Once Daily</title>
          <description>Once daily treatment with oral gliclazide MR 30mg for 12 consecutive weeks.&#xD;
Gliclazide 30mg QD: Gliclazide30mg once daily for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dapagliflozin 10mg Once Daily</title>
          <description>Once daily treatment with oral dapagliflozin (forxiga) 10mg for 12 consecutive weeks.&#xD;
Dapagliflozin 10mg QD: Dapagliflozin 10mg once daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Gliclazide Modified Release 30mg Once Daily</title>
          <description>Once daily treatment with oral gliclazide MR 30mg for 12 consecutive weeks.&#xD;
Gliclazide 30mg QD: Gliclazide30mg once daily for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="7"/>
                    <measurement group_id="B2" value="63" spread="7"/>
                    <measurement group_id="B3" value="63" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glomerular Filtration Rate (GFR) in ml/Min</title>
        <description>Calculated from urinary and plasma inulin concentrations, GFR in ml/min</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 10mg Once Daily</title>
            <description>Once daily treatment with oral dapagliflozin (forxiga) 10mg for 12 consecutive weeks.&#xD;
Dapagliflozin 10mg QD: Dapagliflozin 10mg once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Gliclazide Modified Release 30mg Once Daily</title>
            <description>Once daily treatment with oral gliclazide MR 30mg for 12 consecutive weeks.&#xD;
Gliclazide 30mg QD: Gliclazide30mg once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Glomerular Filtration Rate (GFR) in ml/Min</title>
          <description>Calculated from urinary and plasma inulin concentrations, GFR in ml/min</description>
          <units>ml/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104" spread="17"/>
                    <measurement group_id="O2" value="109" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effective Renal Plasma Flow (ERPF) in ml/Min</title>
        <description>Calculated from urinary and plasma para-aminohippurate concentrations, ERPF in ml/min</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 10mg Once Daily</title>
            <description>Once daily treatment with oral dapagliflozin (forxiga) 10mg for 12 consecutive weeks.&#xD;
Dapagliflozin 10mg QD: Dapagliflozin 10mg once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Gliclazide Modified Release 30mg Once Daily</title>
            <description>Once daily treatment with oral gliclazide MR 30mg for 12 consecutive weeks.&#xD;
Gliclazide 30mg QD: Gliclazide30mg once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Effective Renal Plasma Flow (ERPF) in ml/Min</title>
          <description>Calculated from urinary and plasma para-aminohippurate concentrations, ERPF in ml/min</description>
          <units>ml/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="639" spread="141"/>
                    <measurement group_id="O2" value="678" spread="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fractional Excretion of Sodium in % of Filtered Sodium</title>
        <description>Calculated fractional excretions with measured GFR (see above) and urinary and plasma concentrations of sodium. Fractional excretion in % of filtered sodium</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 10mg Once Daily</title>
            <description>Once daily treatment with oral dapagliflozin (forxiga) 10mg for 12 consecutive weeks.&#xD;
Dapagliflozin 10mg QD: Dapagliflozin 10mg once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Gliclazide Modified Release 30mg Once Daily</title>
            <description>Once daily treatment with oral gliclazide MR 30mg for 12 consecutive weeks.&#xD;
Gliclazide 30mg QD: Gliclazide30mg once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Fractional Excretion of Sodium in % of Filtered Sodium</title>
          <description>Calculated fractional excretions with measured GFR (see above) and urinary and plasma concentrations of sodium. Fractional excretion in % of filtered sodium</description>
          <units>% of filtered sodium</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="0.19"/>
                    <measurement group_id="O2" value="0.66" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fractional Excretion of Potassium in % of Filtered Potassium</title>
        <description>Calculated fractional excretions with measured GFR (see above) and urinary and plasma concentrations of potassium. Fractional excretion in % of filtered potassium</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 10mg Once Daily</title>
            <description>Once daily treatment with oral dapagliflozin (forxiga) 10mg for 12 consecutive weeks.&#xD;
Dapagliflozin 10mg QD: Dapagliflozin 10mg once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Gliclazide Modified Release 30mg Once Daily</title>
            <description>Once daily treatment with oral gliclazide MR 30mg for 12 consecutive weeks.&#xD;
Gliclazide 30mg QD: Gliclazide30mg once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Fractional Excretion of Potassium in % of Filtered Potassium</title>
          <description>Calculated fractional excretions with measured GFR (see above) and urinary and plasma concentrations of potassium. Fractional excretion in % of filtered potassium</description>
          <units>% of filtered potassium</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" spread="3.3"/>
                    <measurement group_id="O2" value="11.8" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fractional Excretion of Glucose in % of Filtered Glucose</title>
        <description>Calculated fractional excretions with measured GFR (see above) and urinary and plasma concentrations of glucose. Fractional excretion in % of filtered glucose</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 10mg Once Daily</title>
            <description>Once daily treatment with oral dapagliflozin (forxiga) 10mg for 12 consecutive weeks.&#xD;
Dapagliflozin 10mg QD: Dapagliflozin 10mg once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Gliclazide Modified Release 30mg Once Daily</title>
            <description>Once daily treatment with oral gliclazide MR 30mg for 12 consecutive weeks.&#xD;
Gliclazide 30mg QD: Gliclazide30mg once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Fractional Excretion of Glucose in % of Filtered Glucose</title>
          <description>Calculated fractional excretions with measured GFR (see above) and urinary and plasma concentrations of glucose. Fractional excretion in % of filtered glucose</description>
          <units>% of filtered glucose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1" spread="15.6"/>
                    <measurement group_id="O2" value="0.6" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Albumin-Creatinine Ratio in mg/mmol</title>
        <description>Calculated from measured urinary albumin and creatinin concentrations, in mg/mmol</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 10mg Once Daily</title>
            <description>Once daily treatment with oral dapagliflozin (forxiga) 10mg for 12 consecutive weeks.&#xD;
Dapagliflozin 10mg QD: Dapagliflozin 10mg once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Gliclazide Modified Release 30mg Once Daily</title>
            <description>Once daily treatment with oral gliclazide MR 30mg for 12 consecutive weeks.&#xD;
Gliclazide 30mg QD: Gliclazide30mg once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Albumin-Creatinine Ratio in mg/mmol</title>
          <description>Calculated from measured urinary albumin and creatinin concentrations, in mg/mmol</description>
          <units>mg/mmol</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" lower_limit="0.31" upper_limit="1.48"/>
                    <measurement group_id="O2" value="0.54" lower_limit="0.31" upper_limit="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neutrophil Gelatinase-associated Lipocalin (NGAL)</title>
        <description>NGAL (ng/mmoll) measured in urine as a marker of renal damage</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 10mg Once Daily</title>
            <description>Once daily treatment with oral dapagliflozin (forxiga) 10mg for 12 consecutive weeks.&#xD;
Dapagliflozin 10mg QD: Dapagliflozin 10mg once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Gliclazide Modified Release 30mg Once Daily</title>
            <description>Once daily treatment with oral gliclazide MR 30mg for 12 consecutive weeks.&#xD;
Gliclazide 30mg QD: Gliclazide30mg once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Neutrophil Gelatinase-associated Lipocalin (NGAL)</title>
          <description>NGAL (ng/mmoll) measured in urine as a marker of renal damage</description>
          <units>ng/mmol</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.76" lower_limit="2.24" upper_limit="5.84"/>
                    <measurement group_id="O2" value="3.79" lower_limit="2.80" upper_limit="6.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kidney Injury Molecule-1 (KIM-1) in ng/mmol</title>
        <description>KIM-1 (ng/mmol) measured in urine as a marker of renal damage</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 10mg Once Daily</title>
            <description>Once daily treatment with oral dapagliflozin (forxiga) 10mg for 12 consecutive weeks.&#xD;
Dapagliflozin 10mg QD: Dapagliflozin 10mg once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Gliclazide Modified Release 30mg Once Daily</title>
            <description>Once daily treatment with oral gliclazide MR 30mg for 12 consecutive weeks.&#xD;
Gliclazide 30mg QD: Gliclazide30mg once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Kidney Injury Molecule-1 (KIM-1) in ng/mmol</title>
          <description>KIM-1 (ng/mmol) measured in urine as a marker of renal damage</description>
          <units>ng/mmol</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" lower_limit="0.105" upper_limit="0.288"/>
                    <measurement group_id="O2" value="0.265" lower_limit="0.160" upper_limit="0.548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Body Weight</title>
        <description>Measured in kilograms</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 10mg Once Daily</title>
            <description>Once daily treatment with oral dapagliflozin (forxiga) 10mg for 12 consecutive weeks.&#xD;
Dapagliflozin 10mg QD: Dapagliflozin 10mg once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Gliclazide Modified Release 30mg Once Daily</title>
            <description>Once daily treatment with oral gliclazide MR 30mg for 12 consecutive weeks.&#xD;
Gliclazide 30mg QD: Gliclazide30mg once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight</title>
          <description>Measured in kilograms</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.7" spread="16.9"/>
                    <measurement group_id="O2" value="99.6" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Systolic Blood Pressure</title>
        <description>Blood pressure will be measured using an automated oscillometric blood pressure device (Dinamap®) in mmHg</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 10mg Once Daily</title>
            <description>Once daily treatment with oral dapagliflozin (forxiga) 10mg for 12 consecutive weeks.&#xD;
Dapagliflozin 10mg QD: Dapagliflozin 10mg once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Gliclazide Modified Release 30mg Once Daily</title>
            <description>Once daily treatment with oral gliclazide MR 30mg for 12 consecutive weeks.&#xD;
Gliclazide 30mg QD: Gliclazide30mg once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>Blood pressure will be measured using an automated oscillometric blood pressure device (Dinamap®) in mmHg</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.2" spread="10.7"/>
                    <measurement group_id="O2" value="131.1" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dapagliflozin 10mg Once Daily</title>
          <description>Once daily treatment with oral dapagliflozin (forxiga) 10mg for 12 consecutive weeks.&#xD;
Dapagliflozin 10mg QD: Dapagliflozin 10mg once daily for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Gliclazide Modified Release 30mg Once Daily</title>
          <description>Once daily treatment with oral gliclazide MR 30mg for 12 consecutive weeks.&#xD;
Gliclazide 30mg QD: Gliclazide30mg once daily for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>genital fungal infections</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>For GFR measurements, iohexol was used instead of inulin because inulin was retracted for human use during the trial. This did not alter our findings.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Erik van Bommel</name_or_title>
      <organization>AmsterdamUMC</organization>
      <phone>+31 20 444 2264</phone>
      <email>e.vanbommel@amsterdamumc.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

